Head to Head Comparison: Array BioPharma (ARRY) versus The Competition
Array BioPharma (NASDAQ: ARRY) is one of 294 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Array BioPharma to related businesses based on the strength of its dividends, profitability, analyst recommendations, institutional ownership, valuation, earnings and risk.
This is a summary of current ratings and recommmendations for Array BioPharma and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Array BioPharma Competitors||729||3174||11805||264||2.73|
Array BioPharma presently has a consensus target price of $13.86, indicating a potential upside of 12.48%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.52%. Given Array BioPharma’s rivals higher probable upside, analysts clearly believe Array BioPharma has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
85.6% of Array BioPharma shares are held by institutional investors. Comparatively, 51.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.2% of Array BioPharma shares are held by insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Array BioPharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Array BioPharma Competitors||-5,449.91%||-447.34%||-41.78%|
Risk and Volatility
Array BioPharma has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500. Comparatively, Array BioPharma’s rivals have a beta of 6.57, meaning that their average stock price is 557% more volatile than the S&P 500.
Valuation and Earnings
This table compares Array BioPharma and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Array BioPharma||$43.66 million||-$100.01 million||-17.11|
|Array BioPharma Competitors||$473.33 million||$171.77 million||-7.05|
Array BioPharma’s rivals have higher revenue and earnings than Array BioPharma. Array BioPharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Array BioPharma rivals beat Array BioPharma on 8 of the 12 factors compared.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.